Levodropropizine-d5

Levodropropizine-d5 ((S) - (-) -Dropropizine-d5) is deuterium labeled Levodropropizine. Levodropropizine (DF-526) is an orally active histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive agent[1].

Product Specifications

Product Name Alternative

(S) - (-) -Dropropizine-d5; DF-526-d5

UNSPSC

12352005

Target

Histamine Receptor; Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology; Inflammation/Immunology; Neurological Disease

Smiles

OC[C@@H](O)CN1CCN(C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])CC1

Molecular Formula

C13H15D5N2O2

Molecular Weight

241.34

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Luo YL, et al. Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure. Inflamm Res. 2013 Dec;62 (12) :1053-61.|[3]Erdogan MA, et al. Levodropropizine suppresses seizure activity in rats with pentylenetetrazol-induced epilepsy. Epilepsy Res. 2019 Feb;150:32-37. |[4]Yamawaki I, et al. Levodropropizine reduces capsaicin- and substance P-induced plasma extravasation in the rat trachea. Eur J Pharmacol. 1993 Oct 12;243 (1) :1-6. |[5]Zanasi A, et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015 May 31;10 (1) :19.